亚洲房颤患者使用标准剂量与低剂量非维生素K口服抗凝药后的结局
该研究基于韩国国民健康保险服务数据库,纳入56 504例未接受过抗凝治疗的高血栓栓塞风险非瓣膜性房颤患者,比较标准剂量与低剂量NOAC及华法林的有效性和安全性。结果显示NOAC较华法林显著降低血栓栓塞事件风险,达比加群和艾多沙班重大出血风险更低,但利伐沙班无此优势;在<75岁无慢性肾病的成人中,低剂量艾多沙班较华法林无临床获益。
要点
- NOAC较华法林显著降低血栓栓塞事件风险,达比加群和艾多沙班重大出血风险更低
- 低剂量NOAC使用更普遍,但低剂量艾多沙班在部分人群中无临床获益
- 利伐沙班未显示较华法林降低重大出血风险
核心结论
- 在东亚非瓣膜性房颤患者中,NOAC较华法林具有更好的有效性和安全性结局。
- 低剂量NOAC使用更频繁,但不合理的低剂量艾多沙班似乎导致临床获益降低。
研究设计与样本
- 基于韩国国民健康保险服务数据库(2015年7月1日至2016年12月31日)的全国性行政索赔数据。
- 纳入56 504例未接受过抗凝治疗、CHA2DS2-VASc评分≥2的非瓣膜性房颤患者。
主要发现
- 中位随访15.0个月,达比加群(HR 0.76;95%CI 0.75-0.81)、利伐沙班(HR 0.74;95%CI 0.65-0.83)和艾多沙班(HR 0.68;95%CI 0.59-0.78)均与血栓栓塞事件风险显著降低相关。
- 达比加群(HR 0.81;95%CI 0.69-0.95)和艾多沙班(HR 0.67;95%CI 0.56-0.79)与重大出血风险降低相关,利伐沙班(HR 0.96;95%CI 0.84-1.11)则无此关联。
- 在<75岁无慢性肾病的成人中,低剂量艾多沙班较华法林在血栓栓塞事件(HR 0.99;95%CI 0.76-1.28)和死亡率(HR 0.85;95%CI 0.62-1.16)方面未显示临床获益。
关键数值与推荐
- 低剂量NOAC使用比例:达比加群75.1%,利伐沙班59.7%,艾多沙班62.7%。
- NOAC使用分布:达比加群12 593例(22.3%),利伐沙班21 000例(37.2%),艾多沙班12 502例(22.1%),华法林10 409例(18.4%)。
临床怎么用
- 东亚非瓣膜性房颤患者优先考虑NOAC而非华法林以改善有效性和安全性。
- 应避免不合理的低剂量艾多沙班,尤其在<75岁无慢性肾病患者中。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background and Purpose- Limited data are available describing the relative effectiveness, safety, and optimal dosing of non-vitamin K antagonist oral anticoagulants (NOACs) for treatment of nonvalvular atrial fibrillation in East Asian patients. We tried to compare effectiveness and safety outcomes of standard- and low-dose NOACs and warfarin in this population. Methods- Using nationwide administrative claims-based datasets from the Korean National Health Insurance Service Database (July 1, 2015, to December 31, 2016), this study comprised 56 504 anticoagulation-naive nonvalvular atrial fibrillation patients with high thromboembolic risk (CHA2DS2-VASc score, ≥2) treated with oral anticoagulants. Main study outcomes included thromboembolic events (ischemic stroke or systemic embolism), major bleeding, and mortality. Results- Among the study patients, 10 409 (18.4%) received warfarin and 46 095 (81.6%) were treated with NOACs: dabigatran (n=12 593; 22.3%), rivaroxaban (n=21 000; 37.2%), and apixaban (n=12 502; 22.1%). Low-dose NOAC (75.1% dabigatran, 59.7% rivaroxaban, and 62.7% apixaban) was more frequently used than standard-dose NOAC. During median follow-up of 15.0 months, each NOAC was associated with significantly lower risk of thromboembolic events (hazard ratio [HR], 0.76; 95% CI, 0.75-0.81 for dabigatran; HR, 0.74; 95% CI, 0.65-0.83 for rivaroxaban; and HR, 0.68; 95% CI, 0.59-0.78 for apixaban). Regarding safety outcomes, dabigatran (HR, 0.81; CI, 0.69-0.95) and apixaban (HR, 0.67; CI, 0.56-0.79) were associated with lower risk of major bleeding but not with rivaroxaban (HR, 0.96; CI, 0.84-1.11). Among adults <75 years of age without chronic kidney disease, use of low-dose apixaban did not demonstrate clinical benefit over warfarin with respect to thromboembolic events (HR, 0.99; CI, 0.76-1.28) and mortality (HR, 0.85; CI, 0.62-1.16). Conclusions- In this cohort of East Asian patients with nonvalvular atrial fibrillation, NOACs were associated with better effectiveness and safety outcomes versus warfarin. Lower NOAC doses were more often used, but an unjustified underdosing of apixaban seems to result in lower clinical benefit.
引用
- Cho MS, Yun JE, Park JJ, et al. Outcomes After Use of Standard- and Low-Dose Non-Vitamin K Oral Anticoagulants in Asian Patients With Atrial Fibrillation. Stroke. 2018. PMID: 30580716. doi:10.1161/STROKEAHA.118.023093
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。